Key facts
- Notable investors include Investissement Quebec, Anges Québec, Seido Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Innospera Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Innospera Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innospera Pharma
Operator of a biopharmaceutical company intended for the treatment of chronic inflammatory and metabolic conditions. The company focuses on regulating signaling pathways involved in inflammation and tissue scarring, using a library of drug-like compounds to influence receptor behavior, support immune system balance, and reduce fibrotic activity, enabling healthcare providers to access new therapeutic approaches for persistent diseases that currently have limited treatment options.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2019
- Employees
- 7
- Website
- innospera.com/
- Ownership
- Privately Held (backing)
Innospera Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innospera Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innospera Pharma in its N-PORT filings yet. We sweep new filings monthly.